Zobrazeno 1 - 10
of 110
pro vyhledávání: '"Otto, Metzger Filho"'
Autor:
Otto Metzger-Filho, Katharine Collier, Sarah Asad, Peter J. Ansell, Mark Watson, Junu Bae, Mathew Cherian, Joyce O’Shaughnessy, Michael Untch, Hope S. Rugo, Jens B. Huober, Mehra Golshan, William M. Sikov, Gunter von Minckwitz, Priya Rastogi, Lang Li, Lijun Cheng, David Maag, Norman Wolmark, Carsten Denkert, W. Fraser Symmans, Charles E. Geyer, Sibylle Loibl, Daniel G. Stover
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-6 (2021)
Abstract In the BrighTNess trial, carboplatin added to neoadjuvant chemotherapy (NAC) was associated with increased pathologic complete response (pCR) rates in patients with stage II/III triple-negative breast cancer (TNBC). In this matched cohort st
Externí odkaz:
https://doaj.org/article/c6af5c9ea1394c7ab85bf5141ac651b6
Autor:
Michalina Janiszewska, Shayna Stein, Otto Metzger Filho, Jennifer Eng, Natalie L. Kingston, Nicholas W. Harper, Inga H. Rye, Maša Alečković, Anne Trinh, Katherine C. Murphy, Elisabetta Marangoni, Simona Cristea, Benjamin Oakes, Eric P. Winer, Ian E. Krop, Hege G. Russnes, Paul T. Spellman, Elmar Bucher, Zhi Hu, Koei Chin, Joe W. Gray, Franziska Michor, Kornelia Polyak
Publikováno v:
JCI Insight, Vol 6, Iss 11 (2021)
Despite the availability of multiple human epidermal growth factor receptor 2–targeted (HER2-targeted) treatments, therapeutic resistance in HER2+ breast cancer remains a clinical challenge. Intratumor heterogeneity for HER2 and resistance-conferri
Externí odkaz:
https://doaj.org/article/ced21837b6ad4073a0511b1ee2946f97
Autor:
Francesca Poggio, Lucia Del Mastro, Florentine S Hilbers, Saranya Chumsri, Noam F Pondé, Dominique Agbor-Tarh, Otto Metzger-Filho, Larissa A Korde, Olena Werner, Volker Moebus, Alvaro Moreno-Aspitia, Martine J Piccart
Publikováno v:
ESMO Open, Vol 5, Iss 6 (2020)
Background In HER2-positive breast cancer, time elapsed between completion of (neo)adjuvant trastuzumab and diagnosis of metastatic disease (‘trastuzumab-free interval’, TFI) is crucial to choose the optimal first-line treatment. Nevertheless, th
Externí odkaz:
https://doaj.org/article/1527dc5a1b994a6ca8d07abfc732dc49
Autor:
Agostina Nardone, Xintao Qiu, Sandor Spisak, Zsuzsanna Nagy, Ariel Feiglin, Avery Feit, Gabriela Cohen Feit, Yingtian Xie, Alba Font-Tello, Cristina Guarducci, Francisco Hermida-Prado, Sudeepa Syamala, Klothilda Lim, Miguel Munoz Gomez, Matthew Pun, MacIntosh Cornwell, Weihan Liu, Aysegul Ors, Hisham Mohammed, Paloma Cejas, Jane B. Brock, Matthew L. Freedman, Eric P. Winer, Xiaoyong Fu, Rachel Schiff, Henry W. Long, Otto Metzger Filho, Rinath Jeselsohn
Publikováno v:
Cancer Res
Most invasive lobular breast cancers (ILC) are of the luminal A subtype and are strongly hormone receptor–positive. Yet, ILC is relatively resistant to tamoxifen and associated with inferior long-term outcomes compared with invasive ductal cancers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0ba56c1184a5cedf045c241e017be95
https://doi.org/10.1158/0008-5472.can-21-3186
https://doi.org/10.1158/0008-5472.can-21-3186
Autor:
Ian E. Krop, Eric P. Winer, Franziska Michor, Kornelia Polyak, Tari A. King, Leila Russo, Patrizia Dell'Orto, Aditya Bardia, Michelle K. DeMeo, Eileen Wrabel, Adrienne G. Waks, Laura M. Spring, Carlos L. Arteaga, Vandana G. Abramson, Ingrid A. Mayer, Denise A. Yardley, Lorenzo Trippa, Shayna Stein, Giuseppe Viale, Otto Metzger Filho
Pattern of HER2 amplification in the subset of HER2 heterogeneous tumors. Heatmap generated using data from central pathology evaluation of HER2 heterogeneity. The graphic includes patients classified as HER2 heterogeneous depicted in each row. The c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e8aedc7b8facd30ae5fdfd8dec38a2a
https://doi.org/10.1158/2159-8290.22538948
https://doi.org/10.1158/2159-8290.22538948
Autor:
Ian E. Krop, Eric P. Winer, Franziska Michor, Kornelia Polyak, Tari A. King, Leila Russo, Patrizia Dell'Orto, Aditya Bardia, Michelle K. DeMeo, Eileen Wrabel, Adrienne G. Waks, Laura M. Spring, Carlos L. Arteaga, Vandana G. Abramson, Ingrid A. Mayer, Denise A. Yardley, Lorenzo Trippa, Shayna Stein, Giuseppe Viale, Otto Metzger Filho
FISH raw counts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70029c4a13c0e215d7eb9c8e6691c2bd
https://doi.org/10.1158/2159-8290.22538927
https://doi.org/10.1158/2159-8290.22538927
Autor:
Ian E. Krop, Eric P. Winer, Franziska Michor, Kornelia Polyak, Tari A. King, Leila Russo, Patrizia Dell'Orto, Aditya Bardia, Michelle K. DeMeo, Eileen Wrabel, Adrienne G. Waks, Laura M. Spring, Carlos L. Arteaga, Vandana G. Abramson, Ingrid A. Mayer, Denise A. Yardley, Lorenzo Trippa, Shayna Stein, Giuseppe Viale, Otto Metzger Filho
Intratumor heterogeneity is postulated to cause therapeutic resistance. To prospectively assess the impact of HER2 (ERBB2) heterogeneity on response to HER2-targeted therapy, we treated 164 patients with centrally confirmed HER2-positive early-stage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a398926894d3f2961bea956ef7d118f7
https://doi.org/10.1158/2159-8290.c.6548945
https://doi.org/10.1158/2159-8290.c.6548945
Autor:
Rinath Jeselsohn, Otto Metzger Filho, Henry W. Long, Rachel Schiff, Xiaoyong Fu, Eric P. Winer, Matthew L. Freedman, Jane B. Brock, Paloma Cejas, Hisham Mohammed, Aysegul Ors, Weihan Liu, MacIntosh Cornwell, Matthew Pun, Miguel Munoz Gomez, Klothilda Lim, Sudeepa Syamala, Francisco Hermida-Prado, Cristina Guarducci, Alba Font-Tello, Yingtian Xie, Gabriela Cohen Feit, Avery Feit, Ariel Feiglin, Zsuzsanna Nagy, Sandor Spisak, Xintao Qiu, Agostina Nardone
Supplementary Table from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::644d4a0422e250cec5f0ba2f7557a6cc
https://doi.org/10.1158/0008-5472.22432398
https://doi.org/10.1158/0008-5472.22432398
Autor:
Rinath Jeselsohn, Otto Metzger Filho, Henry W. Long, Rachel Schiff, Xiaoyong Fu, Eric P. Winer, Matthew L. Freedman, Jane B. Brock, Paloma Cejas, Hisham Mohammed, Aysegul Ors, Weihan Liu, MacIntosh Cornwell, Matthew Pun, Miguel Munoz Gomez, Klothilda Lim, Sudeepa Syamala, Francisco Hermida-Prado, Cristina Guarducci, Alba Font-Tello, Yingtian Xie, Gabriela Cohen Feit, Avery Feit, Ariel Feiglin, Zsuzsanna Nagy, Sandor Spisak, Xintao Qiu, Agostina Nardone
Supplementary Figure from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f3f88a0fff75196b0b08116e20f8d54
https://doi.org/10.1158/0008-5472.22432410.v1
https://doi.org/10.1158/0008-5472.22432410.v1
Data from A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
Autor:
Rinath Jeselsohn, Otto Metzger Filho, Henry W. Long, Rachel Schiff, Xiaoyong Fu, Eric P. Winer, Matthew L. Freedman, Jane B. Brock, Paloma Cejas, Hisham Mohammed, Aysegul Ors, Weihan Liu, MacIntosh Cornwell, Matthew Pun, Miguel Munoz Gomez, Klothilda Lim, Sudeepa Syamala, Francisco Hermida-Prado, Cristina Guarducci, Alba Font-Tello, Yingtian Xie, Gabriela Cohen Feit, Avery Feit, Ariel Feiglin, Zsuzsanna Nagy, Sandor Spisak, Xintao Qiu, Agostina Nardone
Most invasive lobular breast cancers (ILC) are of the luminal A subtype and are strongly hormone receptor–positive. Yet, ILC is relatively resistant to tamoxifen and associated with inferior long-term outcomes compared with invasive ductal cancers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b9f4303f8d7b93b042806e9b013252f7
https://doi.org/10.1158/0008-5472.c.6514143.v1
https://doi.org/10.1158/0008-5472.c.6514143.v1